Pseudohypoparathyroidism secondary prevention: Difference between revisions
Irfan Dotani (talk | contribs) No edit summary |
Mazia Fatima (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pseudohypoparathyroidism}} | {{Pseudohypoparathyroidism}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}}{{Mazia}} | ||
{{ | |||
==Overview== | ==Overview== | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
Monitor therapy with regular serum and urinary [[calcium]] measurements.Pseudohypoparathyroidism type 1b patients at an increased risk of developing [[hyperparathyroidism]] and [[hyperparathyroid]] bone disease should be maintained at sufficient doses of [[calcium]] and [[vitamin D]] to maintain serum [[calcium]] and [[PTH]] levels within the normal range. Monitor therapy with regular serum and urinary [[calcium]] measurements. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
Revision as of 20:28, 28 September 2017
|
Pseudohypoparathyroidism Microchapters |
|
Differentiating Pseudohypoparathyroidism from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Pseudohypoparathyroidism secondary prevention On the Web |
|
American Roentgen Ray Society Images of Pseudohypoparathyroidism secondary prevention |
|
Risk calculators and risk factors for Pseudohypoparathyroidism secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]
Overview
Secondary Prevention
Monitor therapy with regular serum and urinary calcium measurements.Pseudohypoparathyroidism type 1b patients at an increased risk of developing hyperparathyroidism and hyperparathyroid bone disease should be maintained at sufficient doses of calcium and vitamin D to maintain serum calcium and PTH levels within the normal range. Monitor therapy with regular serum and urinary calcium measurements.